Trial site
Michigan Institute of Urology
Troy, Michigan 48084, United StatesNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 24 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Active, not recruiting9 trials
- Recruiting4 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Janssen Research & Development, LLC7 trials
- Sumitomo Pharma America, Inc.2 trials
- Curium US LLC1 trial
- Dendreon1 trial
- Francis Medical Inc.1 trial
- and 5 more
Running trials
Recruiting
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
NCT07725796· Phase 1· UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.· Source
Contact: Danielle Osterhout
Recruiting
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
NCT07309445· Janssen Research & Development, LLC· Source
Contact: Eliza M. Raymundo, MD, DMCC, FPUA, FPCS
Recruiting
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06533644· Phase 2· Syncromune, Inc.· Source
Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT06134232· Phase 2· Dendreon· Source
Contact: Jason Hafron, MD
Active, not recruiting
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848· Phase 1/2· SURGE Therapeutics· Source
Contact: Danielle Osterhout
Active, not recruiting
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
NCT05683691· Francis Medical Inc.· Source
Active, not recruiting
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
NCT05204927· Phase 3· Curium US LLC· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350· Phase 2· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error